title: IgG1, IgG2 and IgM responses to two Haemophilus influenzae type b conjugate vaccines in young infants.
abstract: PRP-meningococcal outer membrane protein complex (PRP-OMPC) and oligosaccharide linked to variant diphtheria toxin (HbOC) Haemophilus influenzae type b (HIB) conjugate vaccines have both been licensed for United States infants at 2 months of age. Differences in serologic responses for these vaccines have been noted with PRP-OMPC producing an early response at 2 months of age and HbOC producing a higher response after a third dose at 6 months of age. To further characterize the nature of these distinct responses, we measured the IgG1, IgG2 and IgM anti-HIB concentrations by enzyme-linked immunosorbent assay after administration of both vaccines. PRP-OMPC produced an IgM and IgG1 anti-HIB response following the initial dose at 2 months of age. After two doses of HbOC an increase in IgG1 and IgM were noted and after a third dose at 6 months of age an IgG2 anti-HIB response occurred. In addition 33 study subjects were boosted with PRP-OMPC at age 18 months and compared with 34 subjects who received only a primary dose. The anti-HIB IgG1 and IgG2 concentrations following the booster dose were both significantly higher for the primed group (P = 0.0001 and P = 0.001, respectively). Both HIB conjugate vaccines produce predominantly IgG1 anti-HIB antibody responses. The early response to PRP-OMPC vaccine at 2 months of age may result from adjuvant characteristics of the OMPC.
authors.affiliation: Laboratory of Infectious Diseases, Dana-Farber Cancer Institute, Boston, MA 02115.
authors.forename: D M
authors.initials: DM
authors.lastname: Ambrosino
authors.forename: S K
authors.initials: SK
authors.lastname: Sood
authors.forename: M C
authors.initials: MC
authors.lastname: Lee
authors.forename: D
authors.initials: D
authors.lastname: Chen
authors.forename: H R
authors.initials: HR
authors.lastname: Collard
authors.forename: D L
authors.initials: DL
authors.lastname: Bolon
authors.forename: C
authors.initials: C
authors.lastname: Johnson
authors.forename: R S
authors.initials: RS
authors.lastname: Daum
mesh_terms: D000907:Antibodies, Bacterial / Q000096:biosynthesis*; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology*; D001426:Bacterial Proteins / Q000276:immunology*; D001428:Bacterial Vaccines / Q000276:immunology*; D018073:Haemophilus Vaccines; D006801:Humans; D007074:Immunoglobulin G / Q000096:biosynthesis; D007075:Immunoglobulin M / Q000096:biosynthesis; D007136:Immunoglobulins / Q000096:biosynthesis*; D007223:Infant; D011135:Polysaccharides, Bacterial / Q000276:immunology*; D011863:Radioimmunoassay; D014611:Vaccination
chemical_list: D000907:Antibodies, Bacterial; D001425:Bacterial Outer Membrane Proteins; D001426:Bacterial Proteins; D001428:Bacterial Vaccines; D018073:Haemophilus Vaccines; C061964:Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007136:Immunoglobulins; D011135:Polysaccharides, Bacterial; C061963:HibTITER protein, Haemophilus influenzae